Foreword
Ciba-Geigy was formed in 1970 by the merger these two formerly separate Swiss companies, who then combined mustered a history and experience around chemicals and pharmaceuticals spanning more than 250 years.
In 1996 Ciba-Geigy merged with the also Swiss Sandoz. The pharmaceutical and agrochemical divisions of both stayed together, and gave birth to the present day colossus, Novartis.
It then made some spin-offs, namely, in 2000, its agrochemical and genetically modified crops business, with the spinout of Syngenta.
Novartis holds 33.3% of the shares of Roche. It also owns 24.9% of Idenix Pharmaceuticals. It also has two significant license agreement with Genentech, a subsidiary of Roche, one of them for Lucentis and the other for Xolair, both of which Novartis markets outside the US. And Alcon, yes the big Alcon, was already the world's largest and most profitable eye care company when… Novartis decided to buy it.
All this to say that, by 2011, Novartis was the World's second largest pharmaceutical company.
And that by 2012, a IMS Health report ranked Novartis as the biggest pharma company. Of them all.
Then again, according to the “2013 Genetic Engineering & Biotechnology News” magazine, Novartis only ranked nº 3, behind the equally colossi “Pfizer” (2) and “Johnson & Johnson” (1). But if we take the “Contract Pharma” magazine, it is listed as nº 2, with “Pfizer” reaching the apex.
Anyway, whatever the podium placement, the fact that Novartis, in 2011, declared an Annual Revenue of US $58,5 billion and Net Income of US $9,2 billion, is then, I dare say … no big surprise.
Also not surprisingly in these hard times we live in, these Colossi are also “Creditors”. As in “State” or “Nations”, creditors.
Because according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), “European states owe €12-15 billion (US $16-20 billion) to the pharma industry, which includes groups like Roche and Novartis.”
There’s no Bigger Money, except for "The Big Boys".
What about the Defense Industry, you may be thinking, surely it “outguns” them ? Think again . If we look at Lockheed Martin (ranked #1 in that business by “Business Insider” magazine), in 2012 they scrapped a flimsy US $2,9 billion profit.
Banking Industry, please ? Ah, now you’re talking. Yes, banks are The Big Boys. In 2013 two US banks did top Novartis net income of 2011. As in just. They were JP Morgan with US $11,8 billion and Wells Fargo with US $10,7 billion.
But do not be impressed ! Since we’re talking about (ahem) a subject that I know a bit of, be advised that even among the Big Boys there are Bigger ones. True mensch ! They are Chinese, and they dwarf the Americans’ strenuous feat. Because the Biggest Boy of them all, the “Industrial Commercial Bank of China”, had in 2012 a neat net income of US $25 billion.
Don’t be alarmed, though. In these rarefied areas where Money talks (literally), they are all cousins. Big Banks own shares of Big Pharmas and Big Pharmas own shares of Big Banks, so in the end we’re always talking about the same “entities”. Or their cousins (ahem).
But I digress.
Point is, pharmaceuticals are one of two, maybe three places, where “the buck stops”. And stays put.
And Novartis is one of the guys that calls its shots.
Be it to treat Man’s or Beast’s whichever infirmities or biological needs, be it of the Body or the Mind …. you name it, they market it. Everywhere. There’s no “First” or “Third” worlds.
There’s a World. And they own it. Period.
Its road to Cure and Health, I mean.
Let’s not jump to false conclusions, please.
(to be continued …. yes, this was just a “Foreword”)
Credits :
http://en.wikipedia.org/wiki/Ciba-Geigy#Ciba-Geigy
http://www.genengnews.com/insight-and-i ... 60/?page=2
http://www.contractpharma.com/heaps/view/542
http://www.swissinfo.ch/eng/business/Re ... d=32185254
http://www.businessinsider.com/top-25-u ... 012-2?op=1
http://www.relbanks.com/top-us-banks/net-income
http://www.rediff.com/money/slide-show/ ... 120113.htm